+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer



Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer



Journal of Clinical Oncology 21(3): 406-412



To investigate the role of thymidylate synthase (TS),p53, and epidermal growth factor receptor (EGF-R) expressions in hepatic tumors in predicting overall survival (OS), progression-free survival (PFS), and hepatic progression-free survival (HPFS) in patients with resectable metastatic colorectal cancer who were randomly assigned to receive either systemic chemotherapy (SYS) alone or systemic and hepatic arterial infusion (HAI+SYS) chemotherapy following liver surgery. Tissues from metastatic tumors were collected during liver resection from 156 patients, and marker expressions were determined using immunohistochemistry on frozen samples. Univariate associations between marker expressions and baseline variables with OS, PFS, and HPFS were examined. Independent predictors of outcome were determined using a multivariate Cox model. In multivariate analyses, TS overexpression was found to be an independent factor of poor prognosis in OS (P <.01), PFS (P =.06), and HPFS (P <.01). In addition, resection margin was a significant independent factor for all three outcomes. Patients who received HAI+SYS experienced delayed progression in general, and in the liver, specifically. Increased levels of serum alkaline phosphatase correlated with hepatic progression. We also found a significant TS-treatment interaction for OS (P =.01) in multivariate analysis. In particular, TS+ patients receiving HAI+SYS had significantly higher survival than those receiving SYS (64 month sv 21 months; P =.01). TS levels in hepatic tumors and resection margin are independent predictors of survival and progression in patients with metastatic colorectal cancer, whereas p53 and EGFR are not independent predictors. Treatment with HAI + SYS significantly improved the survival profile of TS+ patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047785575

Download citation: RISBibTeXText

PMID: 12560427

DOI: 10.1200/JCO.2003.06.060


Related references

Prognostic value of thymidylate synthase (TS) expression on failure-free survival of fluorouracil-treated metastatic colorectal cancer patients. Journal of Clinical Oncology 24(18_suppl): 10011-10011, 2016

Is Survival for Patients with Resectable Lung Metastatic Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the South Australian Metastatic Colorectal Registry. Annals of Surgical Oncology 23(11): 3616-3622, 2018

Thymidylate synthase is a predictor for response and survival of patients with isolated unresectable liver tumors receiving hepatic artery infusion chemotherapy. EJC Supplements 1(5): S72, September, 2003

Prognostic and predictive value of the thymidylate synthase expression in patients with non-metastatic colorectal cancer. European Journal of Surgical Oncology 31(8): 863-868, 2005

Can colorectal cancer patients with thymidylate synthase-overexpressing liver metastases have an overall survival advantage with hepatic arterial infusion alone?. Journal of Clinical Oncology 21(18): 3543-4; Author Reply 3544-5, 2003

Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. International Journal of Cancer 137(6): 1397-1405, 2015

Is Progression-Free Survival the Right End Point in Trials of Patients With Clearly Resectable, Borderline Resectable, and Unresectable Liver-Limited Colorectal Cancer?. Journal of Clinical Oncology 33(21): 2406-2407, 2015

Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer. Journal of Gastroenterology 40(2): 143-147, 2005

p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer. British Journal of Surgery 89(11): 1409-1415, 2002

Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. International Journal of Oncology 28(5): 1303-1310, 2006

Thymidylate synthase expression and prognosis in colorectal cancer: a meta-analysis of colorectal cancer survival data. International Journal of Biological Markers 27(3): E203-E211, 2013

A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. Bmc Cancer 9: 145-145, 2009

Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clinical Cancer Research 9(11): 4116-4124, 2003

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer 124(4): 688-697, 2017

Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites. Clinical Colorectal Cancer 1(3): 169-73; Discussion 174, 2002